Was the PUMA Biotechnology (PBYI) share sale by Allison Dorval made under a trading plan?

Yes. The Form 4 discloses that Dorval’s sale was conducted under a Rule 10b5-1(c) trading plan. The referenced trading plan was adopted on 03-12-2025, indicating the sale was pre-arranged rather than a discretionary market-timing decision.

PUMA Biotechnology (PBYI) director trades shares, receives 27,000 RSUs grant

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

PUMA Biotechnology director Allison Dorval reported both an equity grant and a share sale. On June 11, 2026, she received 27,000 Restricted Stock Units that vest in full on the earlier of the one-year anniversary of grant or the next annual shareholder meeting, subject to continued service. On June 12, 2026, she made an open-market sale of 11,610 common shares at a weighted average price of $7.1989 per share under a Rule 10b5-1(c) trading plan adopted on 03-12-2025. After these transactions, Dorval directly holds 90,780 common shares.

Insider Trade Summary 10b5-1

Net Seller: 11,610 shares ($83,579)

Net Sell 2 txns

Insider Dorval Allison

Role null

Sold 11,610 shs ($84K)

Type	Security	Shares	Price	Value
Sale	Common Stock	11,610	$7.1989	$84K
Grant/Award	Common Stock	27,000	$0.00	--

Holdings After Transaction: Common Stock — 90,780 shares (Direct, null)

Footnotes (1)

Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Adoption date of referenced 10b5-1(c) plan is: 03-12-2025 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.98 to $7.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Key Figures

Shares sold: 11,610 shares Sale price (weighted average): $7.1989 per share Sale price range: $6.98 to $7.32 +3 more

6 metrics

Shares sold 11,610 shares Open-market sale of common stock on June 12, 2026

Sale price (weighted average) $7.1989 per share Open-market sale on June 12, 2026

Sale price range $6.98 to $7.32 Multiple transactions within this range on June 12, 2026

RSUs granted 27,000 units Restricted Stock Units grant on June 11, 2026 at $0.00

Shares held after transactions 90,780 shares Direct ownership after grant and sale

Rule 10b5-1 plan adoption date 03-12-2025 Trading plan governing the June 12, 2026 sale

Key Terms

Restricted Stock Units, Rule 10b5-1(c) plan, weighted average price, open-market sale, +1 more

5 terms

Restricted Stock Units financial

"Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Rule 10b5-1(c) plan regulatory

"Adoption date of referenced 10b5-1(c) plan is: 03-12-2025"

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/15/2026 - 08:09 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dorval Allison

(Last)

(First)

(Middle)

C/O PUMA BIOTECHNOLOGY, INC.

10880 WILSHIRE BOULEVARD, SUITE 1700

(Street)

LOS ANGELES

CALIFORNIA

90024

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PUMA BIOTECHNOLOGY, INC. [ PBYI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/11/2026		A		27,000	A	$0⁽¹⁾	102,390	D
Common Stock	06/12/2026		S⁽²⁾		11,610	D	$7.1989⁽³⁾	90,780	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer.

2. Adoption date of referenced 10b5-1(c) plan is: 03-12-2025

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.98 to $7.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

	/s/ Gordon Esplin as attorney-in-fact for Allison Dorval	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did PUMA Biotechnology (PBYI) director Allison Dorval report?

Allison Dorval reported receiving 27,000 Restricted Stock Units and selling 11,610 PUMA Biotechnology common shares. The RSUs were granted at no cost, while the sale was executed in the open market under a pre-established Rule 10b5-1(c) trading plan.

How many PUMA Biotechnology (PBYI) shares did Allison Dorval sell and at what price?

Allison Dorval sold 11,610 PUMA Biotechnology common shares at a weighted average price of $7.1989 per share. The sale occurred through multiple trades within a price range from $6.98 to $7.32, as disclosed in the Form 4 footnote.

What equity award did Allison Dorval receive from PUMA Biotechnology (PBYI)?

Dorval received a grant of 27,000 Restricted Stock Units of PUMA Biotechnology common stock at a price of $0.00 per unit. These RSUs vest in full on the earlier of the one-year anniversary of grant or the next annual shareholder meeting, subject to continued service.

How many PUMA Biotechnology (PBYI) shares does Allison Dorval hold after the reported transactions?

Following the reported grant and sale, Allison Dorval directly holds 90,780 PUMA Biotechnology common shares. This figure reflects her position after receiving 27,000 Restricted Stock Units and selling 11,610 shares in open-market transactions disclosed in the Form 4.